{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:27:02Z","timestamp":1784093222172,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA138264 (ASP)"],"award-info":[{"award-number":["R01CA138264 (ASP)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-024-00434-5","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:02:33Z","timestamp":1727676153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-6446","authenticated-orcid":false,"given":"Samira","family":"Anbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5480-431X","authenticated-orcid":false,"given":"Hanwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-7512","authenticated-orcid":false,"given":"Theinmozhi","family":"Arulraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Nickaeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minu","family":"Pilvankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-5910","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-9235","authenticated-orcid":false,"given":"Aleksander S.","family":"Popel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang, A. E., Karnell, L. H. & Menck, H. R. The National Cancer Data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 83, 1664\u20131678 (1998).","journal-title":"Cancer"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin, C. C. et al. Incidence of noncutaneous melanomas in the U.S. Cancer 103, 1000\u20131007 (2005).","journal-title":"Cancer"},{"key":"434_CR3","first-page":"2299","volume":"122","author":"C Chattopahdyay","year":"2016","unstructured":"Chattopahdyay, C. et al. Uveal melanoma: from diagnosis to treatment and the science in between. Aust. Art F. Pract. Policies Inst. 122, 2299\u20132312 (2016).","journal-title":"Aust. Art F. Pract. Policies Inst."},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010117","volume":"12","author":"RS Seedor","year":"2020","unstructured":"Seedor, R. S. et al. An outcome assessment of a single institution\u2019s longitudinal experience with uveal melanoma patients with liver metastasis. Cancers 12, 1\u201314 (2020).","journal-title":"Cancers"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","volume":"22","author":"M Diener-West","year":"2004","unstructured":"Diener-West, M. et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J. Clin. Oncol. 22, 2438\u20132444 (2004).","journal-title":"J. Clin. Oncol."},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092557","volume":"12","author":"C Rodriguez-Vidal","year":"2020","unstructured":"Rodriguez-Vidal, C. et al. Treatment of metastatic uveal melanoma: systematic review. Cancers 12, 1\u201322 (2020).","journal-title":"Cancers"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/ijms21030879","volume":"21","author":"A Wessely","year":"2020","unstructured":"Wessely, A. et al. The role of immune checkpoint blockade in uveal melanoma. Int. J. Mol. Sci. 21, 879 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","volume":"32","author":"JM Piulats Rodriguez","year":"2014","unstructured":"Piulats Rodriguez, J. M. et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial. J. Clin. Oncol. 32, 9033 (2014).","journal-title":"J. Clin. Oncol."},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer, L. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS ONE 10, 1\u201313 (2015).","journal-title":"PLoS ONE"},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi, A. P. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122, 3344\u20133353 (2016).","journal-title":"Cancer"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ophtha.2008.10.008","volume":"116","author":"E Weis","year":"2009","unstructured":"Weis, E., Shah, C. P., Lajous, M., Shields, J. A. & Shields, C. L. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology 116, 536\u2013543.e2 (2009).","journal-title":"Ophthalmology"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson, P. et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7, 4624\u20134631 (2016).","journal-title":"Oncotarget"},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/cancers11081061","volume":"11","author":"MF Bakhoum","year":"2019","unstructured":"Bakhoum, M. F. & Esmaeli, B. Molecular characteristics of uveal melanoma: insights from the cancer genome atlas (TCGA) project. Cancers 11, 1061 (2019).","journal-title":"Cancers"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","volume":"9","author":"A Javed","year":"2017","unstructured":"Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9, 1323\u20131330 (2017).","journal-title":"Immunotherapy"},{"key":"434_CR16","doi-asserted-by":"publisher","unstructured":"Orloff, M., Seedor, R. & Sato, T. Review of bi-specific therapies in uveal melanoma. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-022-00442-9 (2022).","DOI":"10.1038\/s41417-022-00442-9"},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton, M. R. et al. Tebentafusp, a TCR\/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869\u20135878 (2020).","journal-title":"Clin. Cancer Res."},{"key":"434_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13235968","volume":"13","author":"D Martinez-Perez","year":"2021","unstructured":"Martinez-Perez, D., Vi\u00f1al, D., Solares, I., Espinosa, E. & Feliu, J. Gp-100 as a novel therapeutic target in uveal melanoma. Cancers 13, 1\u20139 (2021).","journal-title":"Cancers"},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/imm.12779","volume":"152","author":"C Boudousquie","year":"2017","unstructured":"Boudousquie, C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology 152, 425\u2013438 (2017).","journal-title":"Immunology"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939\u20131948 (2022).","journal-title":"J. Clin. Oncol."},{"key":"434_CR21","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"434_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","volume":"108","author":"A Betts","year":"2020","unstructured":"Betts, A. & van der Graaf, P. H. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin. Pharmacol. Ther. 108, 528\u2013541 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"434_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","volume":"21","author":"A Betts","year":"2019","unstructured":"Betts, A. et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART\u00ae. AAPS J. 21, 66 (2019).","journal-title":"AAPS J."},{"key":"434_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-20-0269","volume":"20","author":"AJ van de Vyver","year":"2021","unstructured":"van de Vyver, A. J. et al. Predicting tumor killing and t-cell activation by t-cell bispecific antibodies as a function of target expression: combining in vitro experiments with systems modeling. Mol. Cancer Ther. 20, 357\u2013366 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"434_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini, I. et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. npj Syst. Biol. Appl. 6, 28 (2020).","journal-title":"npj Syst. Biol. Appl."},{"key":"434_CR26","doi-asserted-by":"publisher","unstructured":"Weddell, J. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT Pharmacomet. Syst. Pharmacol. 1\u201312 https:\/\/doi.org\/10.1002\/psp4.12928 (2023).","DOI":"10.1002\/psp4.12928"},{"key":"434_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-020-00450-3","volume":"22","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. A quantitative systems pharmacology model of T cell engager applied to solid tumor. AAPS J. 22, 1\u201316 (2020).","journal-title":"AAPS J."},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-001141","volume":"8","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. J. Immunother. Cancer 8, 1\u201311 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1163432","volume":"14","author":"S Anbari","year":"2023","unstructured":"Anbari, S. et al. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager. Front. Pharmacol. 14, 1\u201310 (2023).","journal-title":"Front. Pharmacol."},{"key":"434_CR30","doi-asserted-by":"publisher","first-page":"104702","DOI":"10.1016\/j.isci.2022.104702","volume":"25","author":"H Wang","year":"2022","unstructured":"Wang, H., Zhao, C., Santa-Maria, C. A., Emens, L. A. & Popel, A. S. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. iScience 25, 104702 (2022).","journal-title":"iScience"},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms9971","volume":"6","author":"D Aran","year":"2015","unstructured":"Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 1\u201312 (2015).","journal-title":"Nat. Commun."},{"key":"434_CR32","doi-asserted-by":"publisher","unstructured":"Arulraj, T. et al. Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.05.21.595235 (2024).","DOI":"10.1101\/2024.05.21.595235"},{"key":"434_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","volume":"6","author":"E Dahl\u00e9n","year":"2018","unstructured":"Dahl\u00e9n, E., Veitonm\u00e4ki, N. & Norl\u00e9n, P. Bispecific antibodies in cancer immunotherapy. Ther. Adv. Vaccines Immunother. 6, 3\u201317 (2018).","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"434_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou, S., Liu, M., Ren, F., Meng, X. & Yu, J. The landscape of bispecific T cell engager in cancer treatment. Biomark. Res. 9, 1\u201323 (2021).","journal-title":"Biomark. Res."},{"key":"434_CR35","doi-asserted-by":"publisher","unstructured":"Morcos, P. N., Li, J., Hosseini, I. & Li, C. C. Quantitative clinical pharmacology of T-cell engaging bispecifics: current perspectives and opportunities. Clin. Transl. Sci. 75\u201385 https:\/\/doi.org\/10.1111\/cts.12877 (2020).","DOI":"10.1111\/cts.12877"},{"key":"434_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000267140","volume":"24","author":"DH Char","year":"1992","unstructured":"Char, D. H., Char, D. H. & Kaleta-Michaels, S. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res. 24, 20\u201326 (1992).","journal-title":"Ophthalmic Res."},{"key":"434_CR37","first-page":"223","volume":"107","author":"E Lagouros","year":"2009","unstructured":"Lagouros, E. et al. Infiltrative T regulatory cells in enucleated uveal melanomas. Trans. Am. Ophthalmol. Soc. 107, 223\u2013228 (2009).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"434_CR38","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1002\/cncr.24999","volume":"116","author":"D Mougiakakos","year":"2010","unstructured":"Mougiakakos, D. et al. Intratumoral forkhead box p3-positive regulatory t cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 116, 2224\u20132233 (2010).","journal-title":"Cancer"},{"key":"434_CR39","unstructured":"European Medicines Agency (EMA). Assessment report (EPAR)\u2014Saphnelo. 31 (EMA, 2022)."},{"key":"434_CR40","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","volume":"99","author":"B Royer-Bertrand","year":"2016","unstructured":"Royer-Bertrand, B. et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am. J. Hum. Genet. 99, 1190\u20131198 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"434_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00008390-199906000-00012","volume":"9","author":"LRHM Schurmans","year":"1999","unstructured":"Schurmans, L. R. H. M. et al. Effects of transpupillary thermotherapy on immunological parameters and apoptosis in a case of primary uveal melanoma. Melanoma Res. 9, 297\u2013302 (1999).","journal-title":"Melanoma Res."},{"key":"434_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1755-3768.2010.02076.x","volume":"89","author":"J Dennaoui","year":"2011","unstructured":"Dennaoui, J. et al. Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma. Acta Ophthalmol. 89, 268\u2013273 (2011).","journal-title":"Acta Ophthalmol."},{"key":"434_CR43","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1167\/iovs.12-10123","volume":"53","author":"N Nagarkatti-Gude","year":"2012","unstructured":"Nagarkatti-Gude, N., Bronkhorst, I. H. G., van Duinen, S. G., Luyten, G. P. M. & Jager, M. J. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Investig. Ophthalmol. Vis. Sci. 53, 6748\u20136755 (2012).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"434_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1089\/jir.2018.0087","volume":"39","author":"MR Zaidi","year":"2019","unstructured":"Zaidi, M. R. The interferon-gamma paradox in cancer. J. Interferon Cytokine Res. 39, 30\u201338 (2019).","journal-title":"J. Interferon Cytokine Res."},{"key":"434_CR45","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/molecules24132450","volume":"24","author":"MC Petralia","year":"2019","unstructured":"Petralia, M. C. et al. Characterization of the pathophysiological role of CD47 in uveal melanoma. Molecules 24, 2450 (2019).","journal-title":"Molecules"},{"key":"434_CR46","doi-asserted-by":"publisher","first-page":"637999","DOI":"10.3389\/fphys.2021.637999","volume":"12","author":"K Azer","year":"2021","unstructured":"Azer, K. et al. History and future perspectives on the discipline of quantitative systems pharmacology modeling and its applications. Front. Physiol. 12, 637999 (2021).","journal-title":"Front. Physiol."},{"key":"434_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10928-021-09785-6","volume":"49","author":"L Cheng","year":"2022","unstructured":"Cheng, L., Qiu, Y., Schmidt, B. J. & Wei, G. W. Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure. J. Pharmacokinet. Pharmacodyn. 49, 39\u201350 (2022).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"434_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields, C. L. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol. 127, 989\u2013998 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"434_CR49","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/archopht.1997.01100160184007","volume":"115","author":"DH Char","year":"1997","unstructured":"Char, D. H., Kroll, S. & Phillips, T. L. Uveal melanoma growth rate and prognosis. Arch. Ophthalmol. 115, 1014\u20131018 (1997).","journal-title":"Arch. Ophthalmol."},{"key":"434_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0210276","volume":"14","author":"MS Basile","year":"2019","unstructured":"Basile, M. S. et al. Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS ONE 14, 1\u201316 (2019).","journal-title":"PLoS ONE"},{"key":"434_CR51","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1158\/0008-5472.CAN-05-2516","volume":"66","author":"S Lepage","year":"2006","unstructured":"Lepage, S. & Lapointe, R. Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res. 66, 2423\u20132432 (2006).","journal-title":"Cancer Res."},{"key":"434_CR52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1006\/clim.2000.4978","volume":"98","author":"L Nicolas","year":"2001","unstructured":"Nicolas, L. et al. Human \u03b3\u03b4 T cells express a higher TCR\/CD3 complex density than \u03b1\u03b2 T cells. Clin. Immunol. 98, 358\u2013363 (2001).","journal-title":"Clin. Immunol."},{"key":"434_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-022-08586-6","volume":"23","author":"H Matsuo","year":"2022","unstructured":"Matsuo, H., Kamatani, T., Hamba, Y., Boroevich, K. A. & Tsunoda, T. Association between high immune activity and worse prognosis in uveal melanoma and low-grade glioma in TCGA transcriptomic data. BMC Genomics 23, 1\u201310 (2022).","journal-title":"BMC Genomics"},{"key":"434_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","volume":"254","author":"S Marino","year":"2008","unstructured":"Marino, S., Hogue, I. B., Ray, C. J. & Kirschner, D. E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254, 178\u2013196 (2008).","journal-title":"J. Theor. Biol."},{"key":"434_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"434_CR56","unstructured":"Regression Learner App. https:\/\/www.mathworks.com\/help\/stats\/regression-learner-app.html."},{"key":"434_CR57","unstructured":"Kassambara, A. ggpubr: \u2018ggplot2\u2019 based publication ready plots. R package version 0.2.2. https:\/\/CRAN.R-project.org\/package=ggpubr (2019)."},{"key":"434_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.adg0289","volume":"9","author":"T Arulraj","year":"2023","unstructured":"Arulraj, T., Wang, H., Emens, L. A., Santa-Maria, C. A. & Popel, A. S. A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Sci. Adv. 9, 1\u201318 (2023).","journal-title":"Sci. Adv."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00434-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:04:53Z","timestamp":1727679893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1038\/s41540-024-00434-5","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P., M.N., J.W., and S.H. are employees of Boehringer Ingelheim Pharmaceuticals, Inc. A.S.P. is a consultant to J&J\/Janssen, Incyte, and AsclepiX Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}